A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

ClinicalTrials.gov ID: NCT04127695

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04127695. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety and tolerability of ABBV-0805 in adult participants with Parkinson's Disease and results from it will help guide the design of future clinical studies. ABBV-0805 is administered every 28 days by intravenous (IV) infusion.

Study identification

NCT ID: NCT04127695
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 1
Lead sponsor: AbbVie; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Parkinson's Disease

Interventions

ABBV-0805 Drug
Placebo ABBV-0805 Drug

Drug

Eligibility (public fields only)

Age range: Up to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 3, 2020 (Actual)
Primary completion: Jun 16, 2020 (Actual)
Completion: Jun 16, 2020 (Actual)
Last update posted: Dec 15, 2021

2020

United States locations

U.S. sites: 5
U.S. states: 4
U.S. cities: 5

Facility	City	State	ZIP	Site status
University of Florida - Archer /ID# 212823	Gainesville	Florida	32610	—
Columbia Univ Medical Center /ID# 212826	New York	New York	10032-3725	—
Duke University Medical Center /ID# 214435	Durham	North Carolina	27705-4410	—
Evergreen Neuroscience Institute /ID# 212827	Kirkland	Washington	98034-3029	—
Inland Northwest Research /ID# 212119	Spokane	Washington	99202-1342	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04127695, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 15, 2021 · Synced Nov 12, 2026